FEMY

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Femasys (FEMY - Research Report), with a price target of $5.00. The company's shares closed yesterday at $1.91.McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Daré Bioscience, and Capricor Therapeutics. According to TipRanks, McCarthy has an average return of -38.2% and a 14.81% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Femasys with a $6.50 average price target, a 240.31% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-femasys-femy?utm_source=advfn.com&utm_medium=referral